JP2017523796A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523796A5
JP2017523796A5 JP2017506955A JP2017506955A JP2017523796A5 JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5 JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5
Authority
JP
Japan
Prior art keywords
seq
following sequence
encephalitis virus
structural protein
equine encephalitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506955A
Other languages
English (en)
Japanese (ja)
Other versions
JP6824154B2 (ja
JP2017523796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/003997 external-priority patent/WO2016021209A1/en
Publication of JP2017523796A publication Critical patent/JP2017523796A/ja
Publication of JP2017523796A5 publication Critical patent/JP2017523796A5/ja
Application granted granted Critical
Publication of JP6824154B2 publication Critical patent/JP6824154B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506955A 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 Active JP6824154B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462035037P 2014-08-08 2014-08-08
US62/035,037 2014-08-08
US201462079128P 2014-11-13 2014-11-13
US62/079,128 2014-11-13
US201562101514P 2015-01-09 2015-01-09
US62/101,514 2015-01-09
US201562120569P 2015-02-25 2015-02-25
US62/120,569 2015-02-25
US201562198949P 2015-07-30 2015-07-30
US62/198,949 2015-07-30
PCT/JP2015/003997 WO2016021209A1 (en) 2014-08-08 2015-08-07 Virus like particle comprising modified envelope protein e3

Publications (3)

Publication Number Publication Date
JP2017523796A JP2017523796A (ja) 2017-08-24
JP2017523796A5 true JP2017523796A5 (enExample) 2018-09-06
JP6824154B2 JP6824154B2 (ja) 2021-02-03

Family

ID=55263499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506955A Active JP6824154B2 (ja) 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子

Country Status (6)

Country Link
US (1) US9969986B2 (enExample)
EP (1) EP3177720B1 (enExample)
JP (1) JP6824154B2 (enExample)
CN (1) CN106795513B (enExample)
TW (1) TWI720946B (enExample)
WO (1) WO2016021209A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ717682A (en) 2012-02-16 2017-10-27 Vlp Therapeutics Llc Virus like particle composition
CN105431535A (zh) 2013-06-03 2016-03-23 Vlp治疗有限责任公司 疟疾疫苗
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
EP3906939A1 (en) 2013-10-11 2021-11-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
US10385101B2 (en) * 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
CN106687590B (zh) 2014-09-11 2021-08-03 Vlp治疗公司 黄热病毒病毒样颗粒
KR102713707B1 (ko) 2014-12-31 2024-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신규 다가 나노입자 기반 백신
US10166281B2 (en) 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2017150683A1 (en) * 2016-03-04 2017-09-08 Vlp Therapeutics, Llc Zika virus virus like particle
WO2017221076A1 (en) * 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
KR20190056382A (ko) 2016-09-02 2019-05-24 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
CN118909082A (zh) * 2017-03-28 2024-11-08 俄亥俄州创新基金会 一种分离的肽
EP3600367A4 (en) * 2017-03-28 2021-01-13 Children's Hospital Medical Center MONOVALENT VLP-BASED EBOLA VACCINES AND THEIR PREPARATION AND USE PROCEDURES
SG11202005792RA (en) * 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
JP2021512966A (ja) * 2018-02-07 2021-05-20 イミュジーン、リミテッドＩｍｕｇｅｎｅ Ｌｉｍｉｔｅｄ ワクチン組成物およびその使用
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
FR3078535B1 (fr) * 2018-03-05 2024-02-09 Peptinov Sas Composition vaccinale anti-pd-l1
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
EP4135847A4 (en) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus vaccine
WO2021221127A1 (en) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy
EP4326858A4 (en) * 2021-04-23 2025-03-12 VLP Therapeutics, Inc. GALECTIN-TARGETED IMMUNOTHERAPY
CN115466330B (zh) * 2021-06-10 2023-10-20 清华大学 一种基于病毒样颗粒呈递冠状病毒受体结合区的冠状病毒亚单位疫苗
EP4377449A1 (en) * 2021-07-26 2024-06-05 Beam Therapeutics, Inc. Pseudotyped recombinant lyssaviruses for gene therapy
WO2023204148A1 (en) * 2022-04-18 2023-10-26 Cyn-K, Llc Treatment of inflammatory conditions
CN116042657A (zh) * 2023-01-16 2023-05-02 上海复诺健生物科技有限公司 自复制信使核糖核酸疫苗
WO2025084276A1 (ja) * 2023-10-16 2025-04-24 Ｃｙｎ－Ｋバイオ株式会社 肥満の処置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
CA2123612C (en) 1991-11-16 2002-06-25 Michel De Wilde Hybrid protein between cs from plasmodium and h bsag
US5580773A (en) 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
AU716466B2 (en) 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
WO1999041383A1 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Antigen library immunization
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
WO2002096939A2 (en) 2001-05-30 2002-12-05 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
US20050031592A1 (en) 2002-11-13 2005-02-10 Doolan Denise L. Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines
MXPA05012754A (es) * 2003-05-29 2006-05-17 Army Medical Res Inst For I Vacunas virales atenuadas vivas para virus de encefalitis equina oriental.
EP1758925A4 (en) 2003-12-01 2009-04-08 Dow Global Technologies Inc PRODUCTION OF A RECOMBINANT ICOSAHEDRIC VIRUS LIKE PARTICLE
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
WO2006088229A1 (ja) 2005-02-16 2006-08-24 The Circle For The Promotion Of Science And Engineering 改変されたウイルスカプシドタンパク質及びその使用
KR101510065B1 (ko) 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP2468765B1 (en) 2006-03-03 2015-04-22 ONO Pharmaceutical Co., Ltd. Tetramer of extracellular domain of PD-L1
US20100120092A1 (en) 2006-08-30 2010-05-13 Hepgenics Pty Ltd. Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
WO2009079185A2 (en) 2007-11-26 2009-06-25 Novartis Vaccines And Diagnostics, Inc. Methods of generating alphavirus particles
SG171828A1 (en) * 2008-11-26 2011-07-28 Us Gov Health & Human Serv Virus like particle compositions and methods of use
KR101691574B1 (ko) * 2008-12-09 2017-01-02 노바백스, 인코포레이티드 변형 ｒｓｖ ｆ 단백질 및 이들의 사용 방법
ES2752323T3 (es) 2009-09-18 2020-04-06 Fraunhofer Usa Inc Partículas de tipo virus que comprenden proteínas diana fusionadas a proteínas de revestimiento de virus vegetales
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
AU2012269907B2 (en) 2011-06-17 2017-05-18 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
CN102321639B (zh) 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
BR112014009887A2 (pt) 2011-10-25 2017-04-25 Florida Gulf Coast Univ vacinmas e métodos para desenvolvimento de vacina para indução de imunidade a todos os sorotipos de virus da dengue
NZ717682A (en) 2012-02-16 2017-10-27 Vlp Therapeutics Llc Virus like particle composition
US9821050B2 (en) 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
CN105431535A (zh) 2013-06-03 2016-03-23 Vlp治疗有限责任公司 疟疾疫苗
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US10060924B2 (en) 2014-03-18 2018-08-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
KR102713707B1 (ko) 2014-12-31 2024-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신규 다가 나노입자 기반 백신
JPWO2016199936A1 (ja) 2015-06-12 2018-04-05 国立大学法人三重大学 ヒトパラインフルエンザ２型ウイルスベクター及びワクチン
WO2016210127A1 (en) 2015-06-25 2016-12-29 Technovax, Inc. Flavivirus and alphavirus virus-like particles (vlps)
JP6896700B2 (ja) 2015-07-16 2021-06-30 バハラ バイオテック インターナショナル リミテッド ワクチン組成物
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
CN106085974B (zh) 2016-06-07 2019-08-09 博奥生物集团有限公司 一种寨卡病毒假病毒颗粒及其制备方法

Similar Documents

Publication Publication Date Title
SG11202003746UA (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
ZA202002249B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP2019194236A5 (enExample)
JP2017048194A5 (enExample)
JP2018024670A5 (enExample)
JP2017514877A5 (enExample)
LT3577124T (lt) Nukleotido hemisulfato druska, skirta hepatito c virusui gydyti
EA201790630A1 (ru) Способы получения рибозидов
ZA202101615B (en) African swine fever virus vaccine
JP2016525888A5 (enExample)
EP4659816A3 (en) MODIFIED CAPSID PROTEINS FOR IMPROVED PARVOVIRUS VECTOR DELIVERY
JP2019524645A5 (enExample)
JP2016153424A5 (enExample)
JP2017186358A5 (enExample)
JP2017532302A5 (enExample)
JP2011527560A5 (enExample)
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA201890527A1 (ru) Терапевтические вакцины против hpv18
LT3512863T (lt) 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu
JP2014028813A5 (enExample)
EP3148566C0 (en) LONG SYNTHETIC PEPTIDES (SLP) FOR THERAPEUTIC VACCINATION PURPOSES AGAINST HEPATITIS B VIRUS INFECTION
JP2017501211A5 (enExample)
JP2018116258A5 (enExample)
JP2018030858A5 (enExample)
HUE052833T2 (hu) Eljárás 2,5-furándikarbonsav (FDCA) elõállítására